COLORADO SPRINGS, Colo.,
July 29, 2014 /PRNewswire/ --
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in
cannabis formulation-based drug development and related consulting,
is extremely excited to report federal cannabis legalization
efforts in U.S. House and Senate to change medical cannabis laws
across the country. This can be a major game changer for Cannabis
Science's efforts to commence its cannabis treatments nationwide
for a number of targeted critical ailments.
U.S. Representative Scott Perry's
introduction of a bill, H.R. 5226, yesterday to remove therapeutic,
low-THC, high-CBD cannabis oil from the relevant definitions of the
federal Controlled Substances Act, thereby permitting treatment
throughout the United States of
seizure disorders with cannabis, while Cannabis Science has
multiple formulations for multiple critical ailments to begin
nationwide distribution through its state by state partners and
ultimate FDA clinical trials. ( www.cannabisscience.com )
These are significant steps towards federal legalization with a
widespread impact on the national status of medical cannabis use,
which will enable Cannabis Science to move swiftly into a position
of great strength to bring its proprietary cannabis formulations to
market.
The three other sponsors of the bill include Representatives
Dana Rohrabacher (R-CA),
Representative Steve Cohen (D-TN),
and Representative Paul Broun, MD
(R-GA).
The Company also commends U.S. Senator Rand Paul's new announcement to introduce a bill
to reschedule cannabis from its Schedule 1 status under the Act and
his recent legislative efforts to protect states that have
legalized medical cannabis.
"After many successful medical cannabis initiatives on the state
level, we are seeing federal lawmakers of both parties actively
legislating for medical cannabis reform on a federal level to help
patients. Cannabis Science supports these federal efforts and
calls on Members of Congress to examine and expand patient-based
research and support these critical bills," said Chad S. Johnson, Esq., Director, COO and General
Counsel, Cannabis Science, Inc.
These lawmakers add additional, active voices in Congress
pressing for medical cannabis reform on a federal level.
Click here to read Representative Perry's official press
release.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.